Chapman Tripp is advising New Zealand healthcare company EBOS Group Ltd. on its proposed $859.8 million purchase of Australian pharmaceuticals wholesaler Symbion Ltd.
EBOS is buying Symbion from The Zuellig Group Inc., a Hong Kong-based investment company, for $679.3 million plus $180.5 million in assumed debt. The transaction is being funded through a combination of cash and the issue of new EBOS shares to Zuellig. After the issue, Zuellig will be a 40 percent shareholder in the enlarged EBOS Group.
The deal, subject to shareholder approval, is expected to close this month.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
